Treatment of hepatocellular carcinoma using arterial chemoembolization with degradable starch microspheres and continuous arterial infusion of 5-fluorouracil

Japanese Journal of Clinical Oncology

Volumn 38, Issue 9, 2008, Pages 596-603

  Ishida, Kiyotaka ^a   Hirooka, Masashi ^a   Hiraoka, Atsushi ^a   Kumagi, Teru ^a   Uehara, Takahide ^a   Hiasa, Yoichi ^a   Horiike, Norio ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Degradable starch microspheres; Hepatic arterial infusion; Hepatocellular carcinoma; Transcatheter arterial embolization

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; CONTRAST MEDIUM; DECARBOXYPROTHROMBIN; FLUOROURACIL; FOLINATE CALCIUM; GRANULOCYTE COLONY STIMULATING FACTOR; KYOWA; MITOMYCIN C; MITOMYCIN S; PENTAZOCINE; RAMOSETRON; STARCH MICROSPHERE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FOLINIC ACID; MICROSPHERE; MITOMYCIN; STARCH;

ABDOMINAL DISCOMFORT; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASCITES; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DRUG FEVER; DRUG RESPONSE; DRUG WITHDRAWAL; DUODENUM ULCER; FEMALE; HUMAN; HYPOALBUMINEMIA; INFECTION; KIDNEY INJURY; LAPAROSCOPIC SURGERY; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TOXICITY; MALE; NAUSEA; PORTAL VEIN THROMBOSIS; RETROSPECTIVE STUDY; SPLENECTOMY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TUMOR REGRESSION; UPPER ABDOMINAL PAIN; BIODEGRADABLE IMPLANT; CASE REPORT; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CANCER; PATHOLOGY; SURVIVAL;

ABSORBABLE IMPLANTS; AGED; ALPHA-FETOPROTEINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; LEUCOVORIN; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; MITOMYCIN; NEOPLASMS, MULTIPLE PRIMARY; RETROSPECTIVE STUDIES; SPLENECTOMY; STARCH; SURVIVAL ANALYSIS; THROMBOCYTOPENIA;

EID: 52449118799     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn076     Document Type: Article

References (41)

1. Ebara M, Ohto M, Sugiura N, Kita K, Yoshikawa M, Okuda K, et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol 1990;5: 616-26.
2. Seki T, Wakabayashi M, Nakagawa T, Itho T, Shiro T, Kunieda K, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994;74:817-25.
3. Rossi S, Di Stasi M, Buscarini E, Quaretti P, Garbagnati F, Squassante L, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 1996;167:759-68.
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
5. Ikeda K, Saitoh S, Tsubota A, Arase Y, Chayama K, Kumada H, et al. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 1993;71:19-25.
6. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983;148:397-401.
7. Hashimoto T, Nakamura H, Hori S, Tomoda K, Nakanishi K, Murakami T, et al. Hepatocellular carcinoma: Efficacy of transcatheter oily chemoembolization in relation to macroscopic and microscopic patterns of tumor growth among 100 patients with partial hepatectomy. Cardiovasc Intervent Radiol 1995;18:82-6.
8. Wakasa K, Sakurai M, Kuroda C, Marukawa T, Monden M, Okamura J, et al. Effect of transcatheter arterial embolization on the boundary architecture of hepatocellular carcinoma. Cancer 1990;65:913-9.
9. Sato Y, Fujiwara K, Ogata I, Ohta Y, Hayashi S, Oka Y, et al. Transcatheter arterial embolization for hepatocellular carcinoma. Benefits and limitations for unresectable cases with liver cirrhosis evaluated by comparison with other conservative treatments. Cancer 1985;55:2822-5.
10. Patt YZ, Claghorn L, Charnsangavej C, Soski M, Cleary K, Mavligit GM. Hepatocellular carcinoma. A retrospective analysis of treatments to manage disease confined to the liver. Cancer 1988;61:1884-8.
11. Lai EC, Choi TK, Cheng CH, Mok FP, Fan ST, Tan ES. Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil. Cancer 1990;66:1685-7.
12. Falkson G, MacIntyre JM, Moertel CG, Johnson LA, Scherman RC. Primary liver cancer. An Eastern Cooperative Oncology Group Trial. Cancer 1984;54:970-7.
13. Melia WM, Johnson PJ, Williams R. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 1987;71:1213-6.
14. O'Connell MJ, Hahn RG, Rubin J, Moertel CG. Chemotherapy of malignant hepatomas with sequential intraarterial doxorubicin and systemic 5-fluorouracil and semustine. Cancer 1988;62:1041-3.
15. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28.
16. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996;77:2217-22.
17. Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997;79:1890-6.
18. Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, et al. Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 1999;6:587-91.
19. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, et al. The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 1995;52:295-9.
20. Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998;55:39-47.
21. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Masuhara M, et al. Novel arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Hepatol Res 2002;23:7-17.
22. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002;94:435-42.
23. Sugiura K. Studies in a tumor spectrum. VIII. The effect of mitomycin C on the growth of a variety of mouse, rat, and hamster tumors. Cancer Res 1959;19:438-45.
24. Lindell B, Aronsen KF, Rothman U. Repeated arterial embolization of rat livers by degradable microspheres. Eur Surg Res 1977;9:347-56.
25. Sigurdson ER, Ridge JA, Daly JM. Intra-arterial infusion of doxorubicin with degradable starch microspheres. Improvement of hepatic tumor drug uptake. Arch Surg 1986;121:1277-81.
26. Dakhil S, Ensminger W, Cho K, Niederhuber J, Doan K, Wheeler R. Improved regional selectivity of hepatic arterial BCNU with degradable microspheres. Cancer 1982;50:631-5.
27. Ensminger WD, Gyves JW, Stetson P, Walker-Andrews S. Phase I study of hepatic arterial degradable starch microspheres and mitomycin. Cancer Res 1985;45:4464-7.
28. Wollner IS, Walker-Andrews SC, Smith JE, Ensminger WD. Phase II study of hepatic arterial degradable starch microspheres and mitomycin. Cancer Drug Deliv 1986;4:279-84.
29. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5: 649-55.
30. Stoesslein F, Ditscherlein G, Romaniuk PA. Experimental studies on new liquid embolization mixtures (Histoacryl-Lipiodol, Histoacryl-Pantopaque). Cardiovasc Intervent Radiol 1982;5:264-7.
31. National Cancer Institute-Common Toxcity Criteria. (NCI-CTC) Version 2.0. April 30 1999.
32. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST). J Natl Cancer Inst 2000;92:205-16.
33. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagège H, Dao T, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial. Groupe CHC. J Hepatol 1998;29:129-34.
34. Yamashita Y, Takahashi M, Koga Y, Saito R, Nanakawa S, Hatanaka Y, et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 1991;67:385-91.
35. Kuan HY, Smith DE, Ensmiger WD, Knol JA, DeRemer SJ, Yang Z, et al. Regional pharmacokinetics of 5-bromo-2′-deoxyuridine and 5-fluorouracil in dogs: Hepatic arterial versus portal venous infusions. Cancer Res 1996;56:4724-7.
36. Calabro-Jones PM, Byfield JE, Ward JF, Sharp TR. Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. Cancer Res 1982;42:4413-20.
37. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986;83:8923-5.
38. Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14-20.
39. LoRusso P, Pazdur R, Redman BG, Kinzie J, Vaitkevicius V. Low-dose continuous infusion 5-fluorouracil and cisplatin: Phase II evaluation in advanced colorectal carcinoma. Am J Clin Oncol 1989;12:486-90.
40. Aronsen KF, Hellekant C, Holmberg J, Rothman U, Teder H. Controlled blocking of hepatic artery flow with enzymatically degradable microspheres combined with oncolytic drugs. Eur Surg Res 1979;11:99-106.
41. Furuse J, Ishii H, Satake M, Onaya H, Nose H, Mikami S, et al. Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma. Am J Clin Oncol 2003;26:159-64.